Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.

You may also be interested in...



Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio

BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.

Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio

BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.

Merck Cuts 8 Research, 8 Manufacturing Sites As Part Of Schering Integration

With Schering-Plough integration under way, Merck will phase out research and manufacturing operations in effort to achieve $3.5 billion in savings by 2012.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel